Skip to main content
  • The Use of Bivalirudin in Neurosurgical Patients at High Risk for Heparin Anticoagulation

    Final Number:

    Tariq Janjua MD; Jody Lowary cnrn; Leslie A. Nussbaum MD, PhD; Eric S. Nussbaum MD

    Study Design:
    Clinical Trial

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2012 Annual Meeting

    Introduction: Bivalirudin is an ultra short-acting direct thrombin inhibitor which has been used in place of heparin in selected settings. We describe our preliminary experience with the use of bivalirudin in patients who required anticoagulation for a deep vein thrombosis, a prosthetic heart valve, or a hypercoagulable state but were felt be at high risk for the use of heparin.

    Methods: Eight patients in our neurocritical care unit required anticoagulation but were felt to be poor candidates for heparin either due to heparin-induced thrombocytopenia (HIT) or due to high risk for intracranial hemorrhage. A standard protocol was utilized for bivalirudin using a loading dose of 0.75mg/kg followed by a continuous infusion of 0.15mg/kg/hr. Serial aPTT levels were checked on a routine basis to monitor therapeutic effect. The bivalirudin infusion was continued for a period of 2 days to 2 weeks prior to starting coumadin therapy.

    Results: These patients were in the early postoperative period (within 48 hours) following craniotomy, had suffered a recent large hemispheric infarct with hemorrhagic conversion, or had presented with an acute intracerebral hemorrhage. In this small series of patients, no intracranial hemorrhagic complications were encountered. No patients demonstrated progressive systemic thrombotic issues while on bivalirudin.

    Conclusions: Based on these findings, bivalirudin may represent a reasonable alternative in patients for whom heparin anticoagulation is contraindicated. A larger multicenter trial of bivalirudin in this setting may be appropriate.

    Patient Care: all neurosurgeons are faced at times with the problem of needing to anticoagulate a patient at high risk for intracerebral hemorrhage, often due to recent surgery. Heparin is standard of care, but newer shorter-acting agents have become available which may be safer in this setting. This report reviews our early experience with one such agent which may be a good alternative to heparin in this population.

    Learning Objectives: By the conclusion of this session, participants should be able to: 1) Describe the importance of bivalirudin as an alternative to heparin in high risk neurosurgical patients, 2) Discuss management strategies for neurosurgical patients requiring anticoagulation in the early postoperative setting, 3) Identify treatment options for anticoagulation of patients with acute intracerebral hemorrhage.


We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy